×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Best Penny Stocks Under $0.50 for 2022

These stocks all have a super-low share price of $0.50 or less and are sorted by average trading volume. MarketBeat does not necessarily recommend these penny stocks. These companies are considered the most actively-traded stocks priced under $0.50


Endo International logo

#1 - Endo International

NASDAQ:ENDP
Stock Price: $0.37 (-$0.02)
PE Ratio: -0.12
Market Cap: $86.45 million
Average Trading Volume: 10.00 million shares
Consensus Rating: Hold (1 Buy Ratings, 1 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $3.00 (715.9% Upside)
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Akebia Therapeutics logo

#2 - Akebia Therapeutics

NASDAQ:AKBA
Stock Price: $0.37 (-$0.03)
PE Ratio: -0.23
Market Cap: $67.03 million
Average Trading Volume: 8.65 million shares
Consensus Rating: Hold (0 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.75 (379.2% Upside)
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Clarus Therapeutics logo

#3 - Clarus Therapeutics

NASDAQ:CRXT
Stock Price: $0.39 (-$0.02)
Market Cap: $20.36 million
Average Trading Volume: 7.84 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.90 (1,918.4% Upside)
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
HEXO logo

#4 - HEXO

NYSE:HEXO
Stock Price: $0.24 (+$0.01)
PE Ratio: -0.09
Market Cap: $120.11 million
Average Trading Volume: 7.47 million shares
Consensus Rating: Hold (1 Buy Ratings, 4 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $3.42 (1,326.2% Upside)
HEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. HEXO Corp. has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada.
Electric Last Mile Solutions logo

#5 - Electric Last Mile Solutions

NASDAQ:ELMS
Stock Price: $0.19 (-$0.10)
Market Cap: $24.98 million
Average Trading Volume: 3.37 million shares
Consensus Rating: Hold (0 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.90 (3,562.4% Upside)
Electric Last Mile Solutions, Inc., a commercial electric vehicle solutions company, focuses on designing, engineering, manufacturing, and customizing electric 'last mile' delivery and utility vehicles. It offers Class 1 commercial electric vehicle in the U.S. market and focuses on producing Class 3 Urban Utility electric vehicle. The company is headquartered in Troy, Michigan.
Greenlane logo

#6 - Greenlane

NASDAQ:GNLN
Stock Price: $0.25 (-$0.01)
PE Ratio: -0.30
Market Cap: $30.42 million
Average Trading Volume: 1.79 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.22 (1,186.7% Upside)
Greenlane Holdings, Inc. develops and distributes cannabis accessories, child-resistant packaging, vape solutions, and lifestyle products in the United States, Canada, and Europe. It operates through two segments, Consumer Goods and Industrial Goods. The company provides consumption accessories, vaporizers, pipes, rolling papers and packaging, grinders, and apparel lines, as well as bubblers, rigs, and other smoking and vaporization related accessories and merchandise. It offers its products under the VIBES rolling papers, Pollen Gear, the Marley Natural accessory line, Aerospaced & Groove grinders, Marley Natural, K. Haring Glass Collections, Eyce silicone pipes, Higher Standards, and DaVinci vaporizers brands. The company also operates e-commerce websites, such as Vapor.com, Higherstandards.com, Aerospaced.com, DaVincivaporizer.com, Harringglass.com, Eycemolds.com, Vapor.ca, Vaposhop.com, and Puffitup.com. It serves customers through a network of 8,500 smoke shops, cannabis dispensaries, and specialty retailers. Greenlane Holdings, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida.
Sio Gene Therapies logo

#7 - Sio Gene Therapies

NASDAQ:SIOX
Stock Price: $0.33 (-$0.03)
PE Ratio: -0.39
Market Cap: $24.07 million
Average Trading Volume: 695,958 shares
Consensus Rating: Hold (2 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $4.20 (1,172.7% Upside)
Sio Gene Therapies, Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Gold Standard Ventures logo

#8 - Gold Standard Ventures

NYSEAMERICAN:GSV
Stock Price: $0.37 (+$0.02)
PE Ratio: -12.20
Market Cap: $131.30 million
Average Trading Volume: 604,430 shares
Consensus Rating: Moderate Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $0.84 (130.4% Upside)
Gold Standard Ventures Corp., an exploration stage company, engages in the development of district-scale and other gold-bearing mineral resource properties in Nevada, the United States. Its flagship property is the Railroad-Pinion project covering an area of approximately 53,570 acres located in the Elko County, Nevada. The company was incorporated in 2004 and is headquartered in Vancouver, Canada.
Aptinyx logo

#9 - Aptinyx

NASDAQ:APTX
Stock Price: $0.45 (+$0.02)
PE Ratio: -0.38
Market Cap: $30.14 million
Average Trading Volume: 361,275 shares
Consensus Rating: Moderate Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.67 (948.5% Upside)
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Enjoy Technology logo

#10 - Enjoy Technology

NASDAQ:ENJY
Stock Price: $0.26 (-$0.02)
PE Ratio: -0.11
Market Cap: $31.38 million
Average Trading Volume: 592,992 shares
Consensus Rating: Hold (0 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $5.50 (2,015.4% Upside)
Enjoy Technology, Inc. operates mobile retail stores in the United States, Canada, and the United Kingdom. It assists consumer in evaluating and selecting a range of accessories, media subscriptions, device protection, broadband, and other services. The company was founded in 2015 and is headquartered in Palo Alto, California.
Ascot Resources logo

#11 - Ascot Resources

OTCMKTS:AOTVF
Stock Price: $0.34 (-$0.01)
Average Trading Volume: 270,523 shares
Consensus Rating: Hold (1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.42 (320.4% Upside)
Ascot Resources Ltd. operates as a mineral development and exploration company in the United States and Canada. The company explores for gold, silver, copper, molybdenum, and gravel deposits. It holds 100% interests in the Premier Gold project covering an area of 8,133 hectares located to the northwest of the town of Stewart, British Columbia; and the Red Mountain project covering an area of 17,125 hectares located to the east-northeast of the town of Stewart. The company also holds interests in the Mount Margaret property located to the southwest of the town of Randle in Skamania County in the southwest of Washington State; and the Swamp Point located on the Portland Canal in northwestern British Columbia. Ascot Resources Ltd. was incorporated in 1986 and is headquartered in Vancouver, Canada.
Argonaut Gold logo

#12 - Argonaut Gold

OTCMKTS:ARNGF
Stock Price: $0.45 (+$0.01)
Average Trading Volume: 143,432 shares
Consensus Rating: Moderate Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.63 (483.3% Upside)
Argonaut Gold Inc. is a Canadian company engaged in gold mining, mine development, and mineral exploration activities at gold-bearing mineral properties in North America. Its primary assets include the El Castillo and San Agustin mines, which together form the El Castillo Complex located in Durango, Mexico; the La Colorada mine located in Sonora, Mexico; the Florida Canyon mine in Nevada, the United States; and the Cerro del Gallo project in Guanajuato, Mexico. The advanced exploration projects of the company include the San Antonio project in Baja California Sur, Mexico, the Cerro del Gallo project in the State of Guanajuato, Mexico, the Ana Paula project in the State of Guerrero, Mexico, and the Magino project in the Province of Ontario, Canada. The Company also holds several other exploration stage projects, all of which are located in North America. Argonaut Gold Inc. was founded in 2007 and is headquartered in Reno, Nevada.
Eloxx Pharmaceuticals logo

#13 - Eloxx Pharmaceuticals

NASDAQ:ELOX
Stock Price: $0.24 (-$0.01)
PE Ratio: -0.26
Market Cap: $20.71 million
Average Trading Volume: 222,102 shares
Consensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.52 (954.4% Upside)
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Tullow Oil logo

#14 - Tullow Oil

OTCMKTS:TUWOY
Stock Price: $0.28 (-$0.01)
Market Cap: $795.33 million
Average Trading Volume: 53,033 shares
Consensus Rating: Moderate Buy (5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $82.50 (29,737.3% Upside)
Tullow Oil plc engages in the oil and gas exploration, development, and production activities primarily in Africa and South America. As of December 31, 2021, its portfolio comprised 30 licenses in 8 countries with 30 producing wells. The company was founded in 1985 and is headquartered in London, the United Kingdom.
Trevali Mining logo

#15 - Trevali Mining

OTCMKTS:TREVF
Stock Price: $0.42 (+$0.03)
PE Ratio: 0.88
Market Cap: $41.85 million
Average Trading Volume: 16,165 shares
P/E Ratio: 0.9
Consensus Rating: Hold (0 Buy Ratings, 4 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $1.61 (280.2% Upside)
Trevali Mining Corporation, a base-metals mining company, engages in the acquisition, exploration, development of, and production from mineral properties. It primarily explores for zinc, lead, silver, copper, and gold deposits. The company's operational assets include the 90%-owned Perkoa Mine in Burkina Faso; 90%-owned Rosh Pinah Mine in Namibia; and Caribou Mine in northern New Brunswick, Canada. It also holds interests in the Halfmile, Stratmat, and Restigouche properties situated in New Brunswick, Canada; Gergarub project in Namibia; and Ruttan Mine located in northern Manitoba, Canada. In addition, the company has an option to acquire a 100% interest in the Heath Steele deposit located in New Brunswick, Canada. Trevali Mining Corporation was formerly known as Trevali Resources Corp. and changed its name to Trevali Mining Corporation in April 2011. The company was incorporated in 1964 and is headquartered in Vancouver, Canada.
CubicFarm Systems logo

#16 - CubicFarm Systems

OTCMKTS:CUBXF
Stock Price: $0.30 (-$0.02)
Average Trading Volume: 12,565 shares
Consensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.35 (352.7% Upside)
CubicFarm Systems Corp. develops, manufactures, and sells cubic farming systems for farmers worldwide. The company offers CubicFarm System and CubicFarms' HydroGreen Grow System. Its systems help farmers to produce lettuce, basil, microgreens, nutraceutical ingredients, and animal feed. The company was formerly known as Forty Foot Farms Ltd. and changed its name to CubicFarms Systems Corp. in June 2016. CubicFarms Systems Corp was incorporated in 2015 and is headquartered in Langley, Canada.
Hammerson logo

#17 - Hammerson

OTCMKTS:HMSNF
Stock Price: $0.27 (+$0.01)
Market Cap: $40.61 million
Average Trading Volume: 5,768 shares
Consensus Rating: Hold (0 Buy Ratings, 3 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $33.00 (12,352.8% Upside)
At Hammerson, we create vibrant, continually evolving spaces, in and around major cities, where people and brands want to be. We seek to deliver value for all our stakeholders and to create a positive and sustainable impact for generations to come. We own and operate high-quality flagship destinations and have investments in premium outlets in selected European countries and have a City Quarters strategy to evolve our portfolio beyond retail.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.